References
- Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10–29.
- Saiga K, Matsuda T, Sofue T. Prediction of the future incidence of cancer in Japan. In Sofue T, editor. White paper on cancer and statistics 2012 (in Japanese). Tokyo: Shinohara Shuppan Shin-ha, 2012. p. 63–81.
- Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–92.
- Editorial: To screen or not to screen for prostate cancer? Lancet 2012;379:2024.
- Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/mL: results of a prospective study in a clinical setting. Eur Urol 2011;60:214–22.
- Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate specific antigen range. J Urol 2011;185:1650–5.
- Ito K, Miyakubo M, Sekine Y, Koike H, Matsui H, Shibata Y, Suzuki K. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol 2013;31:305–11.
- Lazzeri M, Haese A, de la Taille A, Paulou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/mL: a multicentric European Study. Euro Urol 2013;63:986–94.
- Kyle KY, Hedvig H. Imaging prostate cancer. Radiol Clin North Am 2000;38:59–85.
- Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59:477–94.
- Choi YJ, Kim JK, Kim N, Choi EK, Cho KS. Functional MR imaging of prostate cancer. Radiographics 2007;27:63–75.
- Abd-Alazeez M, Kirkham A, Ahmed HU, Arya M, Anastasiadis E, Charman SC, et al. Performance of multi-parametric MRI in men at risk of prostate cancer prior to first biopsy: a paired validating cohort study using template prostate mapping biopsies as reference standard. Prostate Cancer Prostatic Dis 2014;17:40–6.
- Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol 2015;195:1428–35.
- Nam RK, Wallis JD, Stojic-Bendavid J, Milot L, Sherman C, Sugar L, Haider MA. A pilot study to evaluate the role of magnetic resonance imaging for prostate cancer screening in the general population. J Urol 2016;196:361–6.
- Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Bürgel H, Darte C, et al. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010;43:926–8.
- Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228–42.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
- Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–8.